Long pediatric treatment exposure documented
Pediatric participants received treatment for a mean of 89 weeks, with exposure ranging from 51 to 133 weeks, providing observations relevant to long-term prophylaxis.
↳ Results, opening paragraphs
Abstract
Background: Hereditary angioedema (HAE) due to C1 inhibitor (C1INH) deficiency is characterized by recurrent attacks of edema of the skin and mucosal tissues. Symptoms usually present during childhood (mean age at first attack, 10 years). Earlier symptom onset may predict a more severe disease course. Subcutaneous (SC) C1INH is indicated for routine prophylaxis to prevent HAE attacks in adolescents and adults. We analyzed the long-term efficacy of C1INH (SC) in subjects ≤17 years old treated in an open-label extension (OLE) of the pivotal phase III Clinical Study for Optimal Management of Preventing Angioedema with Low-Volume Subcutaneous C1 Inhibitor Replacement Therapy (COMPACT) trial. Methods: Eligible subjects (age ≥6 years, with ≥4 attacks over 2 consecutive months before entry into the OLE or placebo-controlled COMPACT trial) were treated with C1INH (SC) 40 or 60 IU/kg twice weekly for 52-140 weeks. Subgroup analyses by age (≤17 vs. >17 years) were performed for key efficacy endpoints. Results: Ten subjects were ≤17 years old [mean (range) age, 13.3 (8-16) years, 3 subjects <12 years old; exposure range, 51-133 weeks]. All 10 pediatric subjects experienced ≥50% reduction (mean, 93%) in number of attacks versus the prestudy period, with a 97% reduction in the median number of attacks/month (0.11). All subjects had <1 attack/4-week period and 4 had <1 attack/year (1 subject was attack free). No subject discontinued treatment due to a treatment-related adverse event. Conclusions: Data from pediatric subjects treated with C1INH (SC) for up to 2.55 years and adult subjects revealed similar efficacy. C1INH (SC) is effective and well tolerated as long-term prophylaxis in children, adolescents, and adults with HAE.
Key Claims
Primary findingTentative
C1INH (SC) is effective and well tolerated as long-term prophylaxis in children, adolescents, and adults with HAE.
unqualified efficacy language exceeds the uncontrolled ten-patient pediatric comparison
Abstract, Conclusions
SecondarySupported
All 10 pediatric subjects experienced ≥50% reduction (mean, 93%) in number of attacks versus the prestudy period, with a 97% reduction in the median number of attacks/month.
directly reported within-subject reductions with no concurrent pediatric control
Abstract; Results, Efficacy Outcomes
SecondaryTentative
Data from pediatric subjects treated with C1INH (SC) for up to 2.55 years and adult subjects revealed similar efficacy.
descriptive subgroup similarity without a formal, adequately powered comparative analysis
Abstract, Conclusions; Discussion, paragraph 1
SecondarySupported
No subject discontinued treatment due to a treatment-related adverse event.
directly observed safety outcome in a small pediatric subgroup
Abstract; Results, Safety Outcomes
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Structured longitudinal outcome capture
Daily electronic diaries, investigator review, a prespecified wash-in period, and six-month SGART and IGART assessments provide a reconstructable longitudinal record.
↳ Methods, COMPACT OLE Study Design
Clear connection to clinical guidance
The paper relates the findings to WAO recommendations, international pediatric consensus guidance, prior intravenous C1INH evidence, and the established COMPACT program.
↳ Background, paragraphs 3–6; Discussion, paragraphs 1 and 6–9
Limitations
Uncontrolled pediatric efficacy comparison
Attack rates during treatment are compared with a prestudy period rather than a concurrent pediatric control, leaving regression to the mean and temporal variability unresolved.
↳ Methods, COMPACT OLE Study Design; Results, Efficacy Outcomes
Very small selected pediatric subgroup
Only ten participants were analyzed, including three children under twelve, and eligibility required frequent prestudy attacks. This sharply limits transferability to the broader pediatric HAE population.
↳ Abstract, Methods, and Results opening paragraphs
Conclusion exceeds subgroup evidence
The Abstract and final Discussion sentence state that C1INH (SC) is effective in pediatric patients without explicitly qualifying the uncontrolled, post hoc design.
↳ Abstract, Conclusions; Discussion, final sentence
Nabu Commentary
The pediatric observations address a clinically relevant gap and include treatment exposure of up to 133 weeks, structured diary recording, and detailed efficacy and safety outcomes. The central methodological constraint is the comparison with a prestudy period in only ten selected participants rather than a concurrent pediatric control. Functional activity measurements help interpret two lower responders but do not resolve regression to the mean, secular attack variation, or extension-study selection. The broad efficacy conclusion and claimed similarity with adults therefore receive less evidentiary weight than the directly reported attack reductions and discontinuation outcome.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Sound3.1
Confidence mediumContribution
3.2
The analysis adds long-term efficacy and safety observations for ten pediatric patients, including three younger than twelve, to an evidence base previously centered on adolescents and adults. Its contribution is incremental because it is a post hoc subgroup of an existing open-label extension rather than a dedicated pediatric comparison.
Background, final paragraph; Results, opening paragraphs
“we evaluated the long-term efficacy and safety of C1INH (SC) in 10 pediatric subjects”
Methodological Rigour
3.2
The study reports dose assignment, wash-in, electronic diary recording, assessment instruments, exposure duration, attack characteristics, and adverse events in useful detail. The prestudy comparison does not address regression to the mean, secular attack variation, altered observation, or selection into the extension, although functional activity is examined for two lower responders.
Methods, COMPACT OLE Study Design; Results, Efficacy Outcomes; Discussion, paragraph 2
“The evaluation period for the efficacy analysis began on day 1 of week 3 of treatment.”
Reporting
3.3
The paper follows a coherent progression from clinical need through methods, results, and interpretation, with specific quantitative reporting. The concluding statement of effectiveness is insufficiently qualified for an uncontrolled pediatric subgroup of ten participants.
Abstract, Conclusions; Discussion, final sentence
“C1INH (SC) is effective and well tolerated as long-term prophylaxis in children”
Positioning
2.8
The Background and Discussion connect the analysis to WAO guidance, pediatric consensus recommendations, intravenous C1INH evidence, and the wider COMPACT program. The Discussion does not explicitly trace the small, selected, uncontrolled subgroup design into the certainty or scope of its pediatric efficacy conclusion.
Background, guideline and COMPACT paragraphs; Discussion, paragraphs 1 and 6–9
“In this pediatric subgroup analysis of an open-label trial, C1INH (SC) was highly effective”
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
The aggregate numerical results are internally consistent, but the certainty of the pediatric efficacy conclusion exceeds the uncontrolled subgroup design. A minor table-number discrepancy does not affect the principal findings.
Research ConductNoted
Trial registration, ethics approval, and written consent are declared. The supplied article identifies the manufacturer's product but contains no explicit funding or conflict-of-interest statement, leaving sponsor relationships incompletely documented in the evaluated text.
Flags: 2 declared / 5 total
Reference IntegrityClean
25 of 25 checkable references verified
29 references in manuscript 4 are books, websites or datasets — counted, but not index-checkable citation details diverge from the cited records for 1 reference
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 18 Sep 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Validated
The product was already approved for routine prophylaxis in adolescents and adults, placing the work near an established clinical pathway. Evidence for younger children remains preliminary because only ten pediatric participants, including three under twelve, were analyzed without a concurrent control.
Background, COMPACT program paragraphs; Results, opening paragraphs
“approved by the US Food and Drug Administration in June 2017”
AI-generated, human-governed. Something look off? Contact us to request a review.